ClinicalTrials.gg
Status unknownNCT05013567PROGELUpdated Mar 21, 2022

Efficacy and Safety Study of Ibuprofen Gel Compared to Placebo in the Treatment of Acute Musculoskeletal Pain

A Phase 3 interventional study of Ibuprofen gel and Placebo in Musculoskeletal Pain, Acute Pain and Stretch, sponsored by Brainfarma Industria Química e Farmacêutica S/A. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.

Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase III clinical trial, multicentre of superiority, randomized, double-blind, parallel groups, placebo-controlled and use of ibuprofen gel in the treatment of acute pain.

Read the detailed description

This study is designed for the relief of acute musculoskeletal pain, characterized by pain in muscles, ligaments, tendons, and nerves.

It is performed in participants of both sexes, over 18 years of age, who have pain of moderate intensity as a result of ankle sprains, upper limb contusions, thigh muscle strains, or torticollis.

The rationale for studying the topical use of ibuprofen is the possibility of an alternative treatment for musculoskeletal pain, avoiding systemic adverse events caused by oral administration.

02

Conditions studied

  • Musculoskeletal Pain
  • Acute Pain
  • Stretch
  • Sprains

Keywords

  • ibuprofen
  • ibuprofen gel
  • pain
03

In context

Musculoskeletal Pain

516 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

This study's planned enrollment of 300 is above the median of 69 across 371 interventional studies indexed under Musculoskeletal Pain.

Browse Musculoskeletal Pain studies →

Lead sponsor

Brainfarma Industria Química e Farmacêutica S/A is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have signed the form;
  • Participants of both genders aged ≥ 18 years;
  • Present acute musculoskeletal pain as a result of: ankle sprains, upper limb contusions, thigh muscle sprains, or torticollis;
  • Present pain of moderate intensity by VAS scale (3 ≤ VAS ≤ 7);
  • Pain onset time is less than 36 hours;
  • Present intact skin at the trauma site;
  • Participants of both sexes with the potential to become pregnant must be truly abstinent or use a highly effective method of throughout the period of 30 days before the administration of the drug until 30 days after the end of treatment;
  • Agree to safety laboratory tests: pregnancy test, complete blood count, and biochemical profile;
  • Be able to understand the nature and purpose of the trial, including the risks and adverse events.

Exclusion criteria

Exclusion Criteria:

  • Participants under the age of 18;
  • Participants with musculoskeletal pain as a result of fractures or dislocations;
  • Participants with mild pain (VAS \< 3) at the time of selection;
  • Participants with severe pain (VAS > 7) at the time of selection;
  • Participants with pain onset time greater than 36 hours;
  • Participants with a history of chronic pain and acute pain spikes;
  • Participants with loss of skin integrity at the trauma site;
  • Have a known reaction to the trial medication or chemically related compounds;
  • Have a prior history of the following comorbidities: asthma or other allergic conditions, uncontrolled heart failure, chronic kidney disease, chronic liver disease, active peptic ulcer disease, or gastrointestinal bleeding;
  • Suspect for COVID-19 according to the criteria defined by the World Health Organization;
  • Regular use of analgesics, non-steroidal analgesics or anticoagulants;
  • Use of oral or topical corticoids in the injured area;
  • Being on medications that have relevant interactions with the trial drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, lithium, methotrexate, acetylsalicylic acid, , oral hypoglycemic agents, beta blockers, angiotensin-converting enzyme inhibitors, antihypertensive agents, and diuretics such as furosemide or thiazide;
  • Have had oral or topical analgesic treatment, including use of non-steroidal analgesics, within 72 hours prior to the screening visit;
  • Participants using traditional Chinese or Japanese therapy (acupuncture);
  • Abusive use of alcoholic beverages;
  • Women who are pregnant, breastfeeding, planning to become pregnant, or who test positive for pregnancy during the trial period;
  • Have participated in a clinical trial within the last 12 months;
  • Have any condition that would preclude participation in the trial in the physician's judgment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ibuprofen gel 5%

    Drug: Ibuprofen gel

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Ibuprofen gel 5% topically four times a day

  • OtherPlacebo

    Placebo gel topically four times a day

06

What researchers measure

Primary outcomes

  1. Superiority of ibuprofen gel over placebo in the treatment of acute musculoskeletal pain.

    The primary endpoint of the study is the proportion of participants achieving at least 50% pain reduction on day 5 of treatment by assessing pain intensity using the Visual Analog Scale (VAS), compared to baseline VAS. (Scale = 0 to 10; 0 = mild pain and 10 = severe pain)

    Time frame: 5 days of treatment

Secondary outcomes

  1. Pain relief with study medication on days 3, 5, and 7.

    Pain relief by the adapted Pain Relief (PAR) Scale, with the 5 categories: 0 - no relief, 1- slight relief, 2 - moderate relief, 3 - considerable relief, and 4 - complete relief, on days 3, 5, and 7.

    Time frame: 3, 5 and 7 days of treatment

  2. Interference of pain on physical activity on days 3, 5 and 7

    Pain interference with physical activity by 4-point scale: 0 - no interference with physical activity; 1 - no restriction of physical activity, although some pain on movement; 2 - some restriction of physical activity, but not enough to prevent normal activity; 3 - unable to perform normal activities and with substantial limiting effects, on days 3, 5, and 7.

    Time frame: 3, 5 and 7 days of treatment

  3. Time needed for pain improvement.

    Time needed for pain improvement (reduction of at least 50% of pain on the VAS scale)

    Time frame: Through study completion, an average of 7 days

  4. Obtain the overall assessment of effectiveness, performed by the participant at the end of the treatment.

    Overall assessment of treatment by participant using 5-point scale: bad, fair, good, very good, and excellent.

    Time frame: Through study completion, an average of 7 days

  5. Obtain the overall efficacy evaluation, performed by the investigator at the end of the treatment.

    Overall assessment of treatment by physician using 5-point scale: bad, fair, good, very good, and excellent.

    Time frame: Through study completion, an average of 7 days

  6. Number of participants using rescue medication.

    Time frame: Through study completion, an average of 7 days

  7. Time to use of rescue medication.

    Time frame: Through study completion, an average of 7 days

Other outcomes

  1. Occurrence of adverse events (AEs) during the study period.

    Rate of occurrence of serious and non-serious AEs, related and unrelated to treatment groups throughout the clinical trial.

    Time frame: Through study completion, an average of 7 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for May 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 19, 2021
StartEst.
Aug 2022
Primary completionEst.
May 2023
CompletionEst.
Jul 2023
Last update
Mar 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05013567
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Aug 2022 (estimated)
Primary completion
May 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
Mar 21, 2022

Study contacts

Cosmed Indústria de Cosméticos e Medicamentos S/A
Contact
juliana.augusto@brainfarma.ind.br
5511 45072111
Brainfarma Indústria Química Farmacêutica
study director · Brainfarma Industria Química e Farmacêutica S/A

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion